Azitra (AZTR) Gains from Investment Securities (2022 - 2025)
Azitra (AZTR) posted Gains from Investment Securities of -$51.0 for Q4 2025, up 61.65% on a QoQ basis from -$133.0 in Q3 2025, and up 32.89% year-over-year from -$38.38 in Q4 2024.
Azitra (AZTR) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Azitra's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$51.0 for Q4 2025.
- Quarterly Gains from Investment Securities rose 32.89% year-over-year to -$51.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$238.0 (up 99.99% YoY) and the FY2025 annual result came in at -$381.0, up 99.99% from the prior year.
- Gains from Investment Securities was -$51.0 for Q4 2025 at Azitra, up from -$133.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $94036.0 in Q2 2023 and bottomed at -$4.0 million in Q3 2024.
- A 4-year average of -$290719.2 and a median of -$393.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities slumped 25293.51% — and 2025, when it jumped 100.0%.
- Azitra's Gains from Investment Securities stood at -$401.0 in 2022, then slumped by 6254.11% to -$25480.0 in 2023, then soared by 99.7% to -$76.0 in 2024, then soared by 32.89% to -$51.0 in 2025.
- Business Quant data shows AZTR's Gains from Investment Securities at -$51.0 in Q4 2025, -$133.0 in Q3 2025, and -$54.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -51.00 |
| Dec 31, 2025 | -51.00 |
| Sep 30, 2025 | -133.00 |
| Sep 30, 2025 | -133.00 |
| Jun 30, 2025 | -54.00 |
| Jun 30, 2025 | -54.00 |
| Mar 31, 2025 | -143.00 |
| Mar 31, 2025 | -143.00 |
| Dec 31, 2024 | -76.00 |
| Dec 31, 2024 | -76.00 |
| Sep 30, 2024 | -4.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -4,372.00 |
| Jun 30, 2024 | -4,372.00 |
| Mar 31, 2024 | -28,155.00 |
| Mar 31, 2024 | -28,155.00 |
| Dec 31, 2023 | -25,480.00 |
| Dec 31, 2023 | -25,480.00 |
| Sep 30, 2023 | -97,765.00 |
| Sep 30, 2023 | -97,765.00 |